Yaichiro Hashimoto1, Atsushi Motegi2, Tetsuo Akimoto2, Norio Mitsuhashi3, Junpei Iizuka4, Kazunari Tanabe4, Yuka Ishii5, Sawa Kono5, Sachiko Izumi5, Kumiko Karasawa5. 1. Department of Radiation Oncology, Tokyo Women's Medical University, 8-1, Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan. hashimoto.yaichiro@twmu.ac.jp. 2. Division of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Chiba, Japan. 3. Radiation Therapy Center, Hitachinaka General Hospital, Ibaraki, Japan. 4. Department of Urology, Tokyo Women's Medical University, Tokyo, Japan. 5. Department of Radiation Oncology, Tokyo Women's Medical University, 8-1, Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.
Abstract
BACKGROUND: Hypofractionated radiotherapy using fewer and larger fractional doses may be more beneficial than conventional external-beam radiotherapy for localized prostate cancer. We evaluated the 5-year outcomes of moderately hypofractionated radiotherapy for localized prostate cancer. METHODS: We retrospectively evaluated 195 patients with localized prostate cancer (T1-3N0M0) who underwent intensity-modulated radiotherapy (IMRT) (66 Gy delivered in fractions of 3 Gy every other weekday) between May 2005 and December 2011. Patients received androgen deprivation therapy depending on the perceived intermediate or high risk of their disease. A prostate-specific antigen nadir +2.0 ng/ml indicated biochemical failure. We assessed toxicity using the Radiation Therapy Oncology Group and the European Organization for Research and Treatment of Cancer (RTOG/EORTC) criteria, and patient-reported outcomes using the Expanded Prostate Cancer Index Composite (EPIC). RESULTS: The risk classifications (proportion) were low risk (13.8%), intermediate risk (35.9%), and high risk (50.3%). The median follow-up was 69 months. Thirteen (6.66%) patients experienced biochemical failure within a median of 40 months (interquartile range, 25-72 months). The 5-year overall survival rate and no biological evidence of disease rate were 97.7% and 92.4%, respectively. Based on the RTOG/EORTC criteria, no patient experienced acute or late toxicity of grade 3 or higher. The EPIC scores revealed significant differences in the average value of all domains (p < 0.01). At 1 month postradiotherapy completion, the general urinary and bowel domain scores had decreased, but these scores returned to baseline level by 3 months post radiotherapy. CONCLUSIONS: The moderately hypofractionated radiotherapy protocol yielded short-term satisfactory clinical outcomes with acceptable toxicity.
BACKGROUND: Hypofractionated radiotherapy using fewer and larger fractional doses may be more beneficial than conventional external-beam radiotherapy for localized prostate cancer. We evaluated the 5-year outcomes of moderately hypofractionated radiotherapy for localized prostate cancer. METHODS: We retrospectively evaluated 195 patients with localized prostate cancer (T1-3N0M0) who underwent intensity-modulated radiotherapy (IMRT) (66 Gy delivered in fractions of 3 Gy every other weekday) between May 2005 and December 2011. Patients received androgen deprivation therapy depending on the perceived intermediate or high risk of their disease. A prostate-specific antigen nadir +2.0 ng/ml indicated biochemical failure. We assessed toxicity using the Radiation Therapy Oncology Group and the European Organization for Research and Treatment of Cancer (RTOG/EORTC) criteria, and patient-reported outcomes using the Expanded Prostate Cancer Index Composite (EPIC). RESULTS: The risk classifications (proportion) were low risk (13.8%), intermediate risk (35.9%), and high risk (50.3%). The median follow-up was 69 months. Thirteen (6.66%) patients experienced biochemical failure within a median of 40 months (interquartile range, 25-72 months). The 5-year overall survival rate and no biological evidence of disease rate were 97.7% and 92.4%, respectively. Based on the RTOG/EORTC criteria, no patient experienced acute or late toxicity of grade 3 or higher. The EPIC scores revealed significant differences in the average value of all domains (p < 0.01). At 1 month postradiotherapy completion, the general urinary and bowel domain scores had decreased, but these scores returned to baseline level by 3 months post radiotherapy. CONCLUSIONS: The moderately hypofractionated radiotherapy protocol yielded short-term satisfactory clinical outcomes with acceptable toxicity.
Entities:
Keywords:
Hypofractionation; Intensity-modulated radiotherapy; Patient-reported outcome; Prostate cancer; Prostate-specific antigen; Quality of life
Authors: Shafak Aluwini; Floris Pos; Erik Schimmel; Stijn Krol; Peter Paul van der Toorn; Hanja de Jager; Wendimagegn Ghidey Alemayehu; Wilma Heemsbergen; Ben Heijmen; Luca Incrocci Journal: Lancet Oncol Date: 2016-03-09 Impact factor: 41.316
Authors: Patrick A Kupelian; Vipul V Thakkar; Deepak Khuntia; Chandana A Reddy; Eric A Klein; Arul Mahadevan Journal: Int J Radiat Oncol Biol Phys Date: 2005-09-19 Impact factor: 7.038
Authors: Raymond Miralbell; Stephen A Roberts; Eduardo Zubizarreta; Jolyon H Hendry Journal: Int J Radiat Oncol Biol Phys Date: 2011-02-15 Impact factor: 7.038
Authors: Nicholas G Zaorsky; Nitin Ohri; Timothy N Showalter; Adam P Dicker; Robert B Den Journal: Cancer Treat Rev Date: 2013-03-01 Impact factor: 12.111
Authors: Nita Patel; Sergio Faria; Fabio Cury; Marc David; Marie Duclos; George Shenouda; Russell Ruo; Luis Souhami Journal: Int J Radiat Oncol Biol Phys Date: 2013-04-15 Impact factor: 7.038
Authors: Anna Wilkins; Helen Mossop; Isabel Syndikus; Vincent Khoo; David Bloomfield; Chris Parker; John Logue; Christopher Scrase; Helen Patterson; Alison Birtle; John Staffurth; Zafar Malik; Miguel Panades; Chinnamani Eswar; John Graham; Martin Russell; Peter Kirkbride; Joe M O'Sullivan; Annie Gao; Clare Cruickshank; Clare Griffin; David Dearnaley; Emma Hall Journal: Lancet Oncol Date: 2015-10-28 Impact factor: 41.316
Authors: Antonio Lazo; Alejandro de la Torre-Luque; Gregorio Arregui; Daniel Rivas; Ana Serradilla; Joaquin Gómez; Francisca Jurado; María Isabel Núñez; Escarlata López Journal: Biology (Basel) Date: 2022-03-11